S. Srivastava

发表

HEPSIN inhibits cell growth/invasion in prostate cancer cells.

V. Srikantan, Michael Valladares, J. Rhim, 2002, Cancer research.

Advances in Brief Dominant Negative Effect of a Germline Mutant p 53 : A Step Fostering Tumorigenesis

S. Srivastava, Shouwen Wang, Y. Tong, 2007 .

Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.

S. Srivastava, Shouwen Wang, Y. Tong, 1993, Cancer research.

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

F. Mostofi, J. Moul, S. Srivastava, 1999, The Journal of urology.

Variation of p53 mutational spectra between carcinoma of the upper and lower respiratory tract.

S. Srivastava, J. Johnson, J. Weissfeld, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

D. Chan, I. Thompson, A. Partin, 2005, Clinical chemistry.

Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.

D. Chan, I. Thompson, A. Partin, 2008, Clinical chemistry.

SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.

D. Chan, I. Thompson, A. Partin, 2008, Clinical chemistry.

Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer

D. McCarthy, I. Thompson, S. Srivastava, 2004, Disease markers.

Prostate cancer: Diagnostic performance of the PCA3 urine test

S. Srivastava, George Leighton Lee, A. Dobi, 2011, Nature Reviews Urology.

PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.

M. Augustus, F. Mostofi, V. Srikantan, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.

N. Tran, S. Srivastava, G. Petrovics, 2006, DNA and cell biology.

Silencing of lactotransferrin expression by methylation in prostate cancer progression

V. Srikantan, S. Srivastava, I. Sesterhenn, 2007, Cancer biology & therapy.

A Role for DNA Methylation in Regulating the Growth Suppressor PMEPA1 Gene in Prostate Cancer

S. Srivastava, Hongyun Li, M. Ehrich, 2007, Epigenetics.

Clinical potential of the ERG oncoprotein in prostate cancer

Isabell A. Sesterhenn, David G. McLeod, S. Srivastava, 2012, Nature Reviews Urology.

Mutational analysis reveals an essential role for the LXXLL motif in the transformation function of the human herpesvirus-8 oncoprotein, kaposin.

S. Srivastava, J. Joseph, A. Srinivasan, 2005, DNA and cell biology.

Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.

Wei Zhang, J. Moul, S. Srivastava, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.

J. Moul, S. Srivastava, R. Connelly, 1999, Urology.

Proteomics in prostate cancer

J. Moul, S. Srivastava, L. Bañez, 2005, Current opinion in urology.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation

S. Srivastava, I. Sesterhenn, I. Sesterhenn, 2008, Oncogene.

Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2017, Journal of molecular biomarkers & diagnosis.

Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer.

S. Srivastava, Ming-Fong Lin, S. Shaheduzzaman, 2005, Endocrine-related cancer.

Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers.

S. Srivastava, J. Johnson, T. Whiteside, 1995, The American journal of pathology.

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

J. Moul, S. Srivastava, I. Sesterhenn, 1994, Cancer research.

Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer

S. Srivastava, H. Geng, M. Venkatachalam, 2019, Genes & cancer.

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.

J. Moul, S. Srivastava, R. Connelly, 1999, The Journal of urology.

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

J. Moul, S. Srivastava, J. Bauer, 1996, Urology.

Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low‐volume tumors

J. Moul, S. Srivastava, I. Sesterhenn, 2010, Pathology international.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma

D. Ornstein, S. Srivastava, I. Sesterhenn, 2009, The Prostate.

Expression during Prostate Cancer Progression Exhibits Cell Growth Inhibitory Function and Decreased PMEPA 1 , an Androgen-regulated NEDD 4-binding Protein

Wei Zhang, J. Moul, S. Srivastava, 2003 .

PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.

Wei Zhang, J. Moul, S. Srivastava, 2003, Cancer research.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression

Thomas L. Fillmore, Richard D. Smith, S. Srivastava, 2020, Cancers.

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

J. Trachtenberg, S. Srivastava, L. Klotz, 2007, British Journal of Cancer.

Role of cell based approaches in cancer immunotherapy

S. Srivastava, A. Srivastava, Rangnath Mishra, 2017 .

Allelic loss on chromosome 6Q in primary prostate cancer

F. Mostofi, V. Srikantan, J. Moul, 1999, International journal of cancer.

Effects of two major activating lesions on the structure and conformation of human ras oncogene products.

S. Srivastava, S. Aaronson, Y. Yuasa, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Variation of p 53 Mutational Spectra between Carcinoma of the Upper and Lower Respiratory Tract

S. Srivastava, J. Weissfeld, R. Ferrell, 2005 .

The Role of Human RAS Proto-Oncogenes in Cancer

S. Srivastava, M. Kraus, S. Aaronson, 1985 .

Normal cells of patients with high cancer risk syndromes lack transforming activity in the NIH/3T3 transfection assay.

S. Srivastava, S. Aaronson, Y. Yuasa, 1983, Science.

H-ras mutants lacking the epitope for the neutralizing monoclonal antibody Y13-259 show decreased biological activity and are deficient in GTPase-activating protein interaction

S. Srivastava, J. Lacal, A. Di Donato, 1989, Molecular and cellular biology.

Analysis of the Biochemical and Biological Activities of Deletion Mutants of the H-Ras P21 Protein Suggest That Gap is an Essential Component of Its Effector Function

S. Srivastava, J. Lacal, A. Donato, 1989 .

Activated H-ras oncogenes in human kidney tumors.

J. Rhim, S. Srivastava, M. Kraus, 1988, Cancer research.

Ras p21 proteins with high or low GTPase activity can efficiently transform NIH 3T3 cells

S. Srivastava, P. Anderson, S. Aaronson, 1986, Cell.

Antibody of predetermined specificity to a carboxy-terminal region of H-ras gene products inhibits their guanine nucleotide-binding function

S. Srivastava, S. Aaronson, J. Lacal, 1985, Molecular and cellular biology.

High frequency of N-ras activation in acute myelogenous leukemia.

S. Srivastava, M. Kraus, S. Aaronson, 1986, Blood.

High frequency of N-ras activation in acute myelogenous leukemia

S. Srivastava, M. Kraus, S. Aaronson, 1986 .

Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1

Wei Zhang, M. Augustus, V. Srikantan, 2000 .

Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated

M. Augustus, V. Srikantan, J. Moul, 2000 .

Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers

S. Srivastava, I. Sesterhenn, Hua Li, 2021, Frontiers in Oncology.

Prostate cancer marker panel with single cell sensitivity in urine

S. Srivastava, I. Sesterhenn, G. Petrovics, 2015, The Prostate.

Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients

S. Srivastava, S. Perner, D. Pfister, 2012 .

Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.

J. Moul, S. Srivastava, R. Connelly, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer.

S. Srivastava, D. Mcleod, 2017, European urology.

A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.

Jack A. Taylor, T. Sellers, J. Carpten, 2020, European urology.

Diagnostic potential of serum proteomic patterns in prostate cancer.

Bao-Ling Adam, Amina Ali, J. Moul, 2003, The Journal of urology.

A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells*

S. Srivastava, Hongyun Li, D. Mcleod, 2008, Journal of Biological Chemistry.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2006, Oncogene.

Monoklonale ERG-Antikörper

S. Srivastava, A. Dobi, Shyh-Han Tan, 2010 .

ERG anticorps monoclonaux

S. Srivastava, A. Dobi, Shyh-Han Tan, 2010 .

Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours

J. Moul, S. Srivastava, U. Engelmann, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.

M. Augustus, V. Srikantan, J. Moul, 2000, The Journal of urology.

Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.

S. Srivastava, Y. Tong, E. Chang, 1993, Oncogene.

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN

S. Srivastava, I. Sesterhenn, Hua Li, 2015, Oncotarget.

Identification of the protein encoded by the human diffuse B-cell lymphoma (dbl) oncogene.

S. Srivastava, S. Aaronson, A. Eva, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.

J. Moul, S. Srivastava, Y. Tong, 1995, Urology.

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

Effects of mutation and growth rates on patterns of microsatellite instability.

L. Aaltonen, S. Srivastava, D. Shibata, 1996, The American journal of pathology.

Comparative efficacy of humalog mix 75/25 with human Insulin

S. Srivastava, P. Wal, A. Wal, 2010 .

Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells.

J. Rhim, S. Srivastava, D. Mcleod, 2008, Experimental cell research.

The human dbl-proto-oncogene product is a cytoplasmic phosphoprotein which is associated with the cytoskeletal matrix.

S. Srivastava, D. Ron, A. Eva, 1989, Oncogene.

ASSESSMENT OF BIOCHEMICAL PARAMETERS IN DRUG INDUCED LIVER TOXICITY AGAINST RAT HEPATOCYTES

S. Srivastava, A. Singh, M. Kaur, 2013 .

ERG Transcription Factor as an Immunohistochemical Marker for Vascular Endothelial Tumors and Prostatic Carcinoma

A. Paetau, S. Srivastava, I. Sesterhenn, 2011, The American journal of surgical pathology.

Ets Family Protein, Erg Expression in Developing and Adult Mouse Tissues by a Highly Specific Monoclonal Antibody

C. Bieberich, V. Vasioukhin, S. Srivastava, 2010, Journal of Cancer.

MOLECULAR ANALYSIS OF P16Ink4/CDKN2 AND P15Ink4B/MTS2 GENES IN PRIMARY HUMAN TESTICULAR GERM CELL TUMORS

J. Moul, S. Srivastava, A. Heidenreich, 1998 .

ORALLY DISINTEGRATING TABLETS; A DOSAGE FORM THAT EXTENDS THE MARKET EXCLUSIVITY AND PATENT PROTECTION

S. Srivastava, V. Chandra, S. Srivastava, 2014 .

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer

S. Srivastava, Hua Li, A. Srinivasan, 2020, Biomolecules.

Analysis of PMEPA1 Isoforms (a and b) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer

Z. Szallasi, S. Srivastava, Hua Li, 2019, Cancers.

Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours.

J. Moul, S. Srivastava, U. Engelmann, 1997, Scandinavian journal of urology and nephrology.

Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol.

S. Srivastava, A. Papas, G. Petrovics, 2006, Life sciences.

Aneuploidy of Chromosome 9 and the Tumor Suppressor Genes p16INK4 and p15INK4B Detected by in situ Hybridization in Locally Advanced Prostate Cancer

J. Moul, S. Srivastava, I. Sesterhenn, 2000, European Urology.

Mutations of the p16 gene product are rare in prostate cancer

J. Moul, S. Srivastava, I. Sesterhenn, 1997, The Prostate.

Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival

S. Srivastava, Y. Shi, D. Mcleod, 2006, Oncogene.

Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.

J. Rhim, J. Moul, S. Srivastava, 2002, International journal of oncology.

Antiproliferation of human prostate cancer cells by ethanolic extracts of Brazilian propolis and its botanical origin.

J. Rhim, S. Srivastava, D. Mcleod, 2007, International journal of oncology.

Novel Liver X Receptor Ligand GAC0001E5 Disrupts Glutamine Metabolism and Induces Oxidative Stress in Pancreatic Cancer Cells

S. Srivastava, J. Gustafsson, Chin-Yo Lin, 2020, International journal of molecular sciences.

Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors

J. Moul, S. Srivastava, A. Heidenreich, 2000, European Urology.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2019, Oncotarget.

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer

Yixue Li, S. Srivastava, Guo-Ping Zhao, 2018, Scientific Reports.

Ethnicity and ERG frequency in prostate cancer

S. Srivastava, A. Dobi, Jason Sedarsky, 2018, Nature Reviews Urology.

TMPRSS2: ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences

R. Hoover, S. Srivastava, I. Sesterhenn, 2017, American journal of epidemiology.

Contribution TMPRSS 2 : ERG Gene Fusions in Prostate Cancer ofWest AfricanMen and aMeta-Analysis of Racial Differences

R. Hoover, S. Srivastava, I. Sesterhenn, 2017 .

Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer

P. Nelson, R. Vessella, L. True, 2016, The Prostate.

Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men

S. Srivastava, G. Petrovics, D. Mcleod, 2013, International journal of molecular sciences.

Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause‐specific mortality

A. Hurtado-coll, S. Srivastava, Ryan R. Gordon, 2013, The Prostate.

Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, Modern Pathology.

A long noncoding RNA connects c-Myc to tumor metabolism

S. Srivastava, H. Kung, G. Petrovics, 2014, Proceedings of the National Academy of Sciences.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

A Urine Exosome Gene Expression Panel Distinguishes Between Indolent and Aggressive Prostate Cancers at Biopsy.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2020, The Journal of urology.

Prognostic features of Annexin A2 expression in prostate cancer.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2020, Pathology.

ERG oncogene modulates prostaglandin signaling in prostate cancer cells

S. Srivastava, I. Sesterhenn, Hua Li, 2011, Cancer biology & therapy.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2005, Oncogene.

Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer

Chen Sun, S. Srivastava, I. Sesterhenn, 2008, Clinical Cancer Research.

ERG Tumor Type is Less Frequent in High Grade and High Stage Prostate Cancers of Chinese Men

S. Srivastava, I. Sesterhenn, Baohong Jiang, 2019, Journal of Cancer.

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities

S. Srivastava, G. Petrovics, Shyh-Han Tan, 2018, International journal of molecular sciences.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men

Z. Szallasi, M. Loda, I. Csabai, 2015, EBioMedicine.

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer

S. Srivastava, I. Sesterhenn, Hua Li, 2014, Epigenetics.

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

S. Srivastava, I. Sesterhenn, R. Pathmanathan, 2015, Molecular and clinical oncology.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India

S. Srivastava, I. Sesterhenn, G. Petrovics, 2013, Journal of Cancer.

Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma

S. Srivastava, J. Kulka, A. Szendrői, 2013, International Urology and Nephrology.

Androgen-Dependent Oncogenic Activation of ETS Transcription Factors by Recurrent Gene Fusions in Prostate Cancer: Biological and Clinical Implications

S. Srivastava, A. Dobi, T. Sreenath, 2013 .

Oncogenic activation of ERG: A predominant mechanism in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2011, Journal of carcinogenesis.

ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor (AR) as a Consequence of Fusion of ERG with AR Regulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors

T. Nikolskaya, Y. Nikolsky, T. Serebryiskaya, 2015, Journal of Cancer.

Evaluation of ERG responsive proteome in prostate cancer

Nicholas B. Griner, S. Srivastava, I. Sesterhenn, 2014, The Prostate.

Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.

J. Strovel, S. Srivastava, C. Dalgard, 2018, Cancer research.

Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells

S. Srivastava, Hua Li, E. Srivatsan, 2017, Molecular Cancer Research.

Increased association of the ERG oncoprotein expression in advanced stages of prostate cancer in Filipinos

M. Lapitan, S. Srivastava, I. Sesterhenn, 2014, The Prostate.

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

P. Kantoff, K. Ardlie, S. Wyman, 2009, Cancer research.

Molecular Genetics and Markers of Progression

M. Augustus, J. Moul, S. Srivastava, 2000 .

Chapter 8 Molecular progression of prostate cancer

J. Moul, S. Srivastava, 1999 .

New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives

S. Srivastava, A. Dobi, Mallesh Pandrala, 2021, ACS medicinal chemistry letters.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

S. Srivastava, I. Sesterhenn, S. Srivastava, 2016, Genes & cancer.

Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1

S. Srivastava, G. Petrovics, A. Dobi, 2016, Oncotarget.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

Nicholas B. Griner, S. Srivastava, I. Sesterhenn, 2014, Molecular Cancer Research.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

S. Srivastava, I. Sesterhenn, J. Vishwanatha, 2014, Molecular Cancer Research.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2014, BMC Cancer.

Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy

J. Moul, S. Srivastava, J. Bauer, 1997, Cancer.

Characterization of frequently deleted 6q locus in prostate cancer.

J. Strovel, M. Augustus, Wei Zhang, 2006, DNA and cell biology.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients

Wei Zhang, V. Srikantan, J. Moul, 2004, Oncogene.

Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

W. Blattner, S. Srivastava, E. Chang, 1990, Nature.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature Genetics.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature genetics.

Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells

Wei Zhang, Wei Zhang, J. Moul, 2002, Oncogene.

Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors.

J. Rhim, S. Srivastava, M. Kraus, 1985, Proceedings of the National Academy of Sciences of the United States of America.

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges

S. Srivastava, G. Petrovics, I. Kohaar, 2019, International journal of molecular sciences.

Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene

J. Rhim, S. Srivastava, E. Reddy, 1983, Nature.

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

S. Srivastava, I. Sesterhenn, S. Shirasawa, 2010, Urology.

PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

W. Zhang, M. Augustus, V. Srikantan, 2000, Cancer research.

ANX7, a candidate tumor suppressor gene for prostate cancer

O. Kallioniemi, M. Raffeld, J. Kononen, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.

P. Febbo, M. Cooperberg, P. Carroll, 2016, Urology.

A novel neoplastic primary tumor-derived human prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2003, International journal of oncology.

Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells

S. Srivastava, Yung-Hyun Choi, P. Seth, 1998, Oncogene.

Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors

S. Srivastava, Z. Weihua, Weihua Zhang, 2019, International journal of molecular sciences.

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2009, Prostate Cancer and Prostatic Diseases.

Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis

S. Srivastava, G. Petrovics, L. Ravindranath, 2007, Journal of Zhejiang University SCIENCE B.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2008, The Journal of urology.

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, The Journal of urology.

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer.

Nan Zhang, Amina Ali, P. Febbo, 2015, European urology.

The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence

S. Srivastava, O. Eidelman, H. Pollard, 2013, International journal of cancer.

Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes

J. Moul, S. Srivastava, D. Mcleod, 2001, International journal of cancer.

A Human Novel Gene DERPC Located on 16q22.1 Inhibits Prostate Tumor Cell Growth and Its Expression Is Decreased in Prostate and Renal Tumors

Wei Zhang, Wei Zhang, J. Moul, 2002, Molecular medicine.

Title Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate

P. Febbo, M. Cooperberg, P. Carroll, 2016 .

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.

W. Isaacs, C. Ewing, J. Rhim, 2006, Experimental cell research.

Predominance of ERG-negative high-grade prostate cancers in African American men.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Molecular and clinical oncology.

Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.

J. Moul, S. Srivastava, A. Heidenreich, 1998, The Journal of urology.

A novel human cancer culture model for the study of prostate cancer

J. Rhim, J. Moul, S. Srivastava, 2001, Oncogene.

Prostate Cancer A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low-and Intermediate-risk Prostate Cancer

P. Febbo, S. Srivastava, I. Sesterhenn, 2015 .

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.

J. Rhim, S. Srivastava, I. Sesterhenn, 2007, Cancer research.

The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research.

S. Srivastava, G. Petrovics, A. Dobi, 2009, Urologic oncology.

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes

S. Srivastava, I. Sesterhenn, H. Pollard, 2022, Nature Communications.

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.

Jacob M. Keaton, Jack A. Taylor, J. Witte, 2023, European urology.

Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2005, Anticancer research.

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer

S. Srivastava, G. Petrovics, 2014, Asian journal of andrology.

Establishment of human retinal pigment epithelial cell lines by oncogenes.

S. Srivastava, A. Srinivasan, K. Dutt, 1990, Oncogene.

Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

J. Moul, S. Srivastava, I. Sesterhenn, 1997, International journal of cancer.

p53‐dependent induction of heat shock protein 27 (HSP27) expression

J. Moul, S. Srivastava, P. Seth, 2000, International journal of cancer.

EVALUATION OF REVERSE TRANSCRIPTASE (RT)-POLYMERASE CHAIN REACTION (PCR)-PROSTATE SPECIFIC ANTIGEN (PSA) ASSAY IN EPITHELIAL CELLS ISOLATED FROM PERIPHERAL BLOOD OF PROSTATE CANCER (CaP) PATIENTS

J. Moul, S. Srivastava, D. Mcleod, 1999 .

Androgen receptor and prostate cancer

S. Srivastava, A. Dobi, E. Richter, 2007, Prostate Cancer and Prostatic Diseases.

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

J. Serth, F. Mostofi, C. Bokemeyer, 2003, Oncology reports.

ANX7 as a Bio-Marker in Prostate and Breast Cancer Progression

O. Kallioniemi, M. Raffeld, L. Bubendorf, 2002, Disease markers.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

S. Srivastava, I. Sesterhenn, S. Perner, 2012, Urology.

A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.

J W Moul, J. Moul, S. Srivastava, 2000, Genomics.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities

S. Srivastava, A. Dobi, T. Sreenath, 2017 .

ERG monoclonal antibody in the diagnosis and biological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity.

S. Srivastava, S. Srivastava, A. Srinivasan, 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome.

S. Srivastava, Kee-Hong Kim, S. Shaheduzzaman, 2008, Cancer biology & therapy.

Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity.

J. Briggs, S. Srivastava, J. Gustafsson, 2020, ACS chemical biology.

African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

Jack A. Taylor, O. Andreassen, R. Eeles, 2020, medRxiv.

Targeted reduction of the EGFR protein, but not inhibition of its kinase activity, induces mitophagy and death of cancer cells through activation of mTORC2 and Akt

J. Briggs, S. Srivastava, Xiongbin Lu, 2018, Oncogenesis.

The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines.

S. Srivastava, Y. Tong, E. Chang, 1992, Carcinogenesis.

Androgen receptor binding sites identified by a GREF_GATA model.

Matthias Frisch, Thomas Werner, T. Werner, 2005, Journal of molecular biology.

Nanotechnology-based approaches for the development of diagnostics, therapeutics, and vaccines.

S. Srivastava, A. Srinivasan, V. Ayyavoo, 2014, Monoclonal antibodies in immunodiagnosis and immunotherapy.

Cadmium-induced neoplastic transformation of human prostate epithelial cells.

J. Rhim, J. Moul, S. Srivastava, 2002, International journal of oncology.

Molecular markers in prostate cancer: the role in preoperative staging.

J. Moul, S. Srivastava, A. Merseburger, 2002, Clinical prostate cancer.

Characterization of unique PMEPA1 gene splice variants (isoforms d and e) from RNA Seq profiling provides novel insights into prognostic evaluation of prostate cancer

Z. Szallasi, S. Srivastava, Hua Li, 2020, Oncotarget.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2017, European urology focus.

Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.

J. Moul, S. Srivastava, J. Bauer, 1998, The Journal of urology.

Prostate Cancer Risk Allele Specific for African Descent Associates with Pathologic Stage at Prostatectomy

S. Srivastava, M. Freedman, Yongmei Chen, 2010, Cancer Epidemiology, Biomarkers & Prevention.

C. elegans hermaphrodites undergo semelparous reproductive death

J. Bähler, S. Srivastava, Marina Ezcurra, 2020, bioRxiv.

Expression of the human dbl-oncogene and proto-oncogene products in insect cells using a baculovirus vector.

S. Srivastava, D. Ron, A. Eva, 1991, Annali dell'Istituto superiore di sanita.

Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.

W. Blattner, S. Srivastava, Y. Tong, 1992, Oncogene.

Abstracts of the 15th Congress of the European Society for Urological Research, Istanbul, October 5–7, 2000

S. Loening, J. Moul, S. Srivastava, 2000, European Urology.

Cellular functions and pathways affected by PCGEM1, a prostate-specific gene associated with African-American prostate cancer patients

Wei Zhang, J. Moul, S. Srivastava, 2004 .

Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.

Cara C. Schafer, S. Srivastava, I. Sesterhenn, 2023, Journal of immunological methods.

Detection of Head and Neck Cancer Based on Longitudinal Changes in Serum Protein Abundance

S. Srivastava, V. Petyuk, Tao Liu, 2020, Cancer Epidemiology, Biomarkers & Prevention.

NIH3T3 fibroblasts transformed by the dbl oncogene show altered expression of bradykinin receptors: effect on inositol lipid turnover.

S. Srivastava, T. Fleming, M. Ruggiero, 1989, Oncogene.

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2020, Journal of Translational Medicine.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

Phosphorylation of ras oncogene product by protein kinase C.

S. Srivastava, P. Blumberg, J. Lacal, 1987, Biochemical and biophysical research communications.

A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.

J. Rhim, J. Moul, S. Srivastava, 2004, International journal of oncology.

p63 expression profile in normal and malignant prostate epithelial cells.

Wei Zhang, J. Rhim, J. Moul, 2002, Anticancer Research.

An Inherited P53 Point Mutation in a Cancer Prone Family with Li-Fraumeni Syndrome

W. Blattner, S. Srivastava, E. Chang, 1991 .

Androgen responsive and refractory prostate cancer cells exhibit distinct curcumin regulated transcriptome

S. Srivastava, Kee-Hong Kim, S. Shaheduzzaman, 2008 .

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Genes & cancer.

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer

S. Srivastava, G. Petrovics, A. Dobi, 2014, BMC Cancer.

Association of TP53 Single Nucleotide Polymorphisms with Prostate Cancer in a Racially Diverse Cohort of Men

S. Srivastava, G. Petrovics, A. Dobi, 2023, Biomedicines.

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer

Qiyuan Li, S. Srivastava, M. Freedman, 2020, Oncotarget.

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

S. Srivastava, I. Sesterhenn, S. Miick, 2010, Clinical Cancer Research.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2007, Urology.

Methylation of TFPI-2 gene is not the sole cause of its silencing.

J. Moul, S. Srivastava, C. N. Rao, 2003, International journal of oncology.

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Jeonifer M. Garren, S. Srivastava, E. Diamandis, 2021, Scientific Reports.

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, Surgery.

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer

Yixue Li, S. Srivastava, Guo-Ping Zhao, 2018, Scientific Reports.

152 ALL-CAUSE MORTALITY AMONG MILITARY HEALTH CARE BENEFICIARIES WITH PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE

S. Srivastava, Yongmei Chen, D. Mcleod, 2011 .

Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor.

W. Blattner, J. Nadeau, C. Pui, 1988, Cancer research.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, S. Srivastava, 2011, Prostate Cancer and Prostatic Diseases.

ERG Expression Levels in Prostate Tumors Reflect Functional Status of the Androgen Receptor (AR) as a Consequence of Fusion of ERG with AR Regulated Gene Promoters

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2010 .

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer

L. Bubendorf, S. Srivastava, I. Sesterhenn, 2014, Prostate Cancer and Prostatic Disease.

Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods

Richard D. Smith, S. Srivastava, D. Camp, 2015, Journal of Translational Medicine.

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2010, Prostate Cancer and Prostatic Diseases.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

S-H Tan, S. Srivastava, I. Sesterhenn, 2010, Prostate Cancer and Prostatic Diseases.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African

S. Srivastava, M. Freedman, I. Sesterhenn, 2018 .

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

S. Srivastava, I. Sesterhenn, S. Miick, 2010, Clinical Cancer Research.

Highlights from the prostate cancer genome report.

S. Srivastava, G. Petrovics, Shyh-Han Tan, 2011, Asian journal of andrology.

Altered messenger RNA and unique mutational profiles of p53 and Rb in human esophageal carcinomas.

T. McDaniel, S. Srivastava, E. Chang, 1993, Cancer research.

Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.

J. Moul, S. Srivastava, J. Bauer, 1998, Urology.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

F. Mostofi, J. Moul, S. Srivastava, 1995, JAMA.

Abstract 3517: A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry

Jack A. Taylor, T. Sellers, J. Carpten, 2020, Epidemiology.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

Z. Szallasi, I. Csabai, G. Klus, 2021, medRxiv.

Characterizing the molecular features of ERG‐positive tumors in primary and castration resistant prostate cancer

P. Nelson, R. Vessella, L. True, 2016, The Prostate.

Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase

V. Srikantan, J. Rhim, S. Srivastava, 2007, Prostate Cancer and Prostatic Diseases.

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

K. D. Sørensen, Jacob M. Keaton, R. Mägi, 2023, Nature Genetics.

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.

J. Moul, S. Srivastava, R. Connelly, 1999, The Journal of urology.

Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation.

J. Moul, S. Srivastava, J. Bauer, 1998, Urology.